Amgen (AMGN) Says FDA Grants Priority Review For its sBLA For Repatha to Include Data On Reducing Risk Of Cardiovascular Events
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Amgen's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE